Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Inqovi Maintenance Therapy in Myeloid Neoplasms

This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. This research study involves the study drug Inqovi, which is a combination of the drugs decitabine …

graft versus host disease
leukemia
cell transplantation
chronic myelomonocytic leukemia
antifungal agents
  • 0 views
  • 17 Oct, 2021
  • 1 location
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bone marrow function …

refractory cytopenia with multilineage dysplasia
azacitidine
cancer
myeloproliferative disorder
blood transfusion
  • 0 views
  • 04 Oct, 2022
  • 1 location
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the

myelofibrosis
gilbert's syndrome
venetoclax
blast cells
decitabine
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and …

remission
acute promyelocytic leukemia
granulocyte colony stimulating factor
refractory acute myeloid leukemia (aml)
azacitidine
  • 41 views
  • 24 Oct, 2022
  • 18 locations
A Study of BGB-11417 in Participants With Myeloid Malignancies

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

azacitidine
myeloid leukemia
leukemia
  • 6 views
  • 04 Oct, 2022
  • 17 locations
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor. One of the approaches to augment graft-versus-leukemia effect the use of post-transplantation bendamustine in graft-versus-host disease prophylaxis. Despite high frequency of responses and durable remissions after this approach majority of patients …

cyclophosphamide
myeloid leukemia
leukemia
cell transplantation
chronic myeloid leukemia
  • 0 views
  • 19 Apr, 2022
  • 1 location
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes. Participants

myeloid leukemia
lenalidomide
growth factor
refractory acute myeloid leukemia (aml)
leukemia
  • 0 views
  • 07 Oct, 2022
  • 7 locations
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

The primary objective is to explore the efficacy and safety of azacytidine and HAG regimen versus azacytidine for elderly patients with Newly Diagnosed MDS/AML/CMML in China. This is a post-marketing, interventional, multi-center, double-arm, prospective, open-label, randomized controlled study in elderly patients with MDS/AML/CMML in China. Patients will be recruited consecutively …

  • 7 views
  • 17 Feb, 2022
  • 1 location
ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center (ATG/PTCy)

A novel regimen, which is composed of a low dose of ATG (5 mg/kg) and low-dose PTCy (one dose of PTCy, 50mg/kg) for GvHD prophylaxis in Haplo-PBSCT for patients with hematologic malignancies, was designed to decrease the risk of aGvHD and lower the incidence of virus reactivation.

  • 0 views
  • 05 Mar, 2022
  • 5 locations
A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms (GO-EXCAP2)

This is a phase 2 randomized controlled trial (RCT) to assess the preliminary efficacy of the a mobile health exercise intervention (GO-EXCAP) versus a chemotherapy education control in 100 older patients with MN receiving outpatient chemotherapy on physical function and patient-reported outcomes (fatigue, mood, and quality of life). We will …

primary cancer
  • 0 views
  • 23 Mar, 2022